LPCN: Lipocine Inc

LPCN新闻

• 12:44 Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
• 23:00 Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
• 13:05 Lipocine completes patient visits in phase 3 trial for PPD treatment
• 12:58 H.C. Wainwright上调Lipocine目标股价至15美元，因PPD试验进展
• 12:56 H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress
• 13:05 Lipocine completes enrollment in phase 3 trial for PPD treatment
• 18:05 利波辛公司产后抑郁症药物试验在安全性评估后继续进行
• 18:03 Lipocine’s PPD drug trial continues after positive safety review
• 13:33 Lipocine公司在产后抑郁症药物试验中完成80%的入组
• 13:31 Lipocine reaches 80% enrollment in postpartum depression drug trial
• 22:19 Lipocine在美国癫痫学会年会上展示LPCN 2101癫痫候选药物数据
• 22:19 Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting
• 13:19 Lipocine公司III期临床试验安全性评估显示PPD治疗结果积极
• 12:32 H.C. Wainwright下调Lipocine目标价至7美元，因PPD试验时间线调整
• 12:31 Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline
• 14:10 Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
• 12:13 Lipocine reports one-third enrollment in PPD treatment trial
• 11:29 Lipocine stock maintains Buy rating at H.C. Wainwright amid Phase 3 progress
• 11:25 Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential
• 11:45 Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins
• 12:13 Lipocine doses first patient in phase 3 trial for oral PPD treatment
• 12:17 Lipocine partner files for Canadian approval of oral TRT drug
• 12:37 Lipocine’s LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
• 12:32 Lipocine to Present at A.G.P.’s Annual Healthcare Company Showcase